Genmab(GMAB) - 2022 Q4 - Earnings Call Transcript

And the first question on the data in relapsed refractory lymphoma and also follicular lymphoma, I will ask Judith to give you a bit more color on timing. Judith. Thank you. And your next question comes from the line of Michael Schmidt from Guggenheim. Please go ahead, your line is open. Thanks, Paul. I will hand over the question to Taham, and then the perhaps Judith can also chip in I think after Taham has already given his initial thoughts on the B7-H4 bispecific program, which we are very excited about. ...